Editas Medicine (EDIT) Return on Sales (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Return on Sales data on file, last reported at 0.04% in Q3 2025.

• On a quarterly basis, Return on Sales rose 1015.0% year-over-year to 0.04% in Q3 2025; TTM through Sep 2025 was 0.05%, a 1.0% decrease from a year earlier, with the FY2024 full-year figure at 0.08%, down 2.0% from the prior year.
• Return on Sales for Q3 2025 stood at 0.04%, up from 0.15% in the prior quarter.
• Over the last five years, Return on Sales for EDIT reached as high as 0.0% in Q4 2023 and fell as low as 378.6% in Q3 2022.
• Historically, Return on Sales has averaged 21.31% across 5 years, with a median of 0.25% in 2023.
• Across the five-year window, Return on Sales slumped 37849 bps in 2022 and surged 37835 bps in 2023, its largest moves.
• Year by year, Return on Sales stood at 0.03% in 2021, then sank by 227 bps to 0.09% in 2022, then surged by 96 bps to 0.0% in 2023, then plunged by 459 bps to 0.02% in 2024, then plunged by 111 bps to 0.04% in 2025.
• Per Business Quant data, the three most recent Return on Sales figures were 0.04% in Q3 2025, 0.15% in Q2 2025, and 0.17% in Q1 2025.